Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyEpidermal Growth Factor Receptor Inhibition (EGFRi) in EGFR–Amplified Gastroesophageal Cancer: Retrospective Global Experience

Sixty patients with EGFR-amplified gastroesophageal adenocarcinoma
(GEA) received EGFRi, including 31 of 60 patients (52%) with concurrent chemotherapy. Across treatment lines, patients achieved a 43% objective response rate with a median PFS of 4.6 months. Typical OS with first-line initiation of non-EGFRi therapy in patients with EGFR-amplified GEA is 11.2 months, as determined by analysis of a deidentified clinicogenomic database. Despite this benefit, analysis of that database for January 2011 through December 2020 suggests that only 5% of patients with EGFR-amplified GEA received EGFRi.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form